Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 6, 2000, Pages 610-620

  Jorga, Karin ^a   Banken, Ludger ^b   Fotteler, Bärbel ^b   Snell, Paul ^b   Steimer, Jean Louis ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; LEVODOPA; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034126571     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.106795     Document Type: Article

References (31)

1. 1. Zürcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, editors. New developments in therapy of Parkinson's disease. Rome: John Libby; 1991. p. 37-43.
2. 2. Da Prada M, Zürcher G, Napolitano A. Tolcapone inhibits both peripheral and central catechol-O-methyltransferase (COMT). Neurology 1995;45(suppl 4):A252-3.
3. 3. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-7.
4. 4. Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 1998;50(suppl 5):S31-8.
5. 5. Jorga K, Fotteler B, Schmitt M, Nielsen T, Zürcher G, Aitken J. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/ benserazide formulations. Eur Neurol 1997;38:59-67.
6. 6. Jorga K, Fotteler B, Sedek G, Nielsen T, Aitken J. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 1998;245:223-30.
7. 7. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.
8. 8. Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, et al. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50:47-55.
9. 9. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997;49:665-71.
10. 10. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-71.
11. 11. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63:421-8.
12. 12. Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 1997;62:300-10.
13. 13. Sedek G, Jorga K, Schmitt M, Burns RS, Leese P. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 1997;20:531-41.
14. 14. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-17.
15. 15. Jorga KM. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin Neuropharmacol 1998; 21(suppl 1):S9-16.
16. 16. Jorga KM, Kroodsma JM, Fotteler B, Heizmann P, Meyer J, Rasch MC, et al. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin Pharmacol Ther 1998;63:646-54.
17. 17. Jorga K, Fotteler B, Banken L, Snell P, Steimer JL. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. Br J Clin Pharmacol 2000;49:39-48.
18. 18. Myllylä VV, Jackson M, Larsen JP, Baas H, Tolcapone International Parkinson's Disease Study (TIPS) Group I. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon: a multicentre, double-blind, randomized, placebo-controlled trial. Eur J Neurol 1997;4:333-41.
19. 19. Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E, Tolcapone in Parkinson's Disease Study Group II (TIPSII). Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Mov Disord 1997;12:928-34.
20. 20. Kurth MC, Adler CH, St Hilaire M, Singer C, Waters C, LeWitt P, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-7.
21. 21. Zürcher G, Da Prada M. Simple automated high-performance liquid chromatograhic column-switching technique for the measurement of dopa and 3-O-methyldopa in plasma. J Chromatogr Biomed Appl 1990;530:253-62.
22. 22. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM users guide part I to VI. San Francisco: Division of Clinical Pharmacology, University of California; 1998.
23. 23. Beal SL, Sheiner L. The NONMEM system. Am Statistician 1980;34:118-9.
24. 24. Da Prada M, Kettler R, Zuercher G, Schaffner R, Haefely WE. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 1987;27:9-20.
25. 25. Karlsson MO, Sheiner LB. The importance of modeling inter-occasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993;21:735-50.
26. 26. Malcom SL, Allen JG, Bird H, Quinn NP, Marion MH, Marsden CD, et al. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and anti-acid on the absorption of Madopar HBS in volunteers. Eur Neurol 1987;27:28-35.
27. 27. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. In: D'Argenio DZ, editor. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. New York: Plenum Press; 1995. p. 69-86.
28. 28. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
29. 29. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996;30:463-81.
30. 30. Dingemanse J, Kleinbloesem CH, Zürcher G, Wood ND, Crevoisier C. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 1997;44:41-8.
31. 31. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43(suppl 6):S23-7.